Curative Effect Observation of Ruxolitinib for Elderly Patients with Myeloproliferative Tumors
Objective Ruxolitinib can be used to treat patients with JAK2 mutation positive myeloproliferative tumors,the study aims to further clarify its effect for JAK2 mutation positive elderly patients.Methods The paper chose 60 elderly MCM patients in our hospital from October 2019 to October 2022.Among them,30 cases in the control group were treated with routine chemotherapy (saledamine+interferon+prednisone),and 30 cases in the experimental group with Ruxolitinib.Three months later,changes in spleen size and adverse reaction indicators based on clinical performance evaluation form (MPN-SAF-TSS) were statistically analyzed and compared between two groups,effect of Ruxolitinib therapy for elderly patients with myeloproliferative tumors was evaluated.Results Our previous research found Ruxolitinib could improve MPN-SAF-TSS symptom scores of elderly patients with myeloproliferative tumors significantly,could shrink spleen of patients effectively,thus achieve effect of "spleen shrinking".The most common side effect of the treatment was anemia and thrombocytopenia,which can be alleviated by adjusting the dosage.Conclusion Ruxolitinib can achieve good better clinical effect than traditional therapy in treatment of elderly patients with myeloproliferative tumors,which has some certain clinical promotion value.
万方数据
维普
